Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone vs Mitoxantrone/Prednisone in Taxane-Resistant Prostate Cancer
NCT00058084Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2003
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ixabepilone in prostate cancer (PCa) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Prostate-Specific Antigen Response up to 3 months. Started Mar 2003; status: completed.
02
Drugs
ixabepilone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00058084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00058084.